Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29